PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.68%
EBIT growth above 1.5x TRAW's 4.46%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
22.68%
Operating income growth above 1.5x TRAW's 4.46%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
22.99%
Net income growth above 1.5x TRAW's 11.91%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
38.32%
EPS growth under 50% of TRAW's 78.16%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
38.32%
Diluted EPS growth under 50% of TRAW's 78.16%. Michael Burry would worry about an eroding competitive position or excessive dilution.
24.80%
Share reduction more than 1.5x TRAW's 303.31%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
24.80%
Diluted share reduction more than 1.5x TRAW's 303.31%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
22.87%
OCF growth 1.25-1.5x TRAW's 16.06%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
22.60%
FCF growth 1.25-1.5x TRAW's 16.06%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13974.70%
Negative 10Y OCF/share CAGR while TRAW stands at 98.10%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
19.53%
Below 50% of TRAW's 99.02%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
73.45%
3Y OCF/share CAGR at 50-75% of TRAW's 98.06%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-5088.50%
Negative 10Y net income/share CAGR while TRAW is at 98.47%. Joel Greenblatt sees a major red flag in long-term profit erosion.
66.11%
5Y net income/share CAGR at 50-75% of TRAW's 98.79%. Martin Whitman might see a shortfall in operational efficiency or brand power.
78.36%
3Y net income/share CAGR 75-90% of TRAW's 98.22%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
2877.65%
Equity/share CAGR of 2877.65% while TRAW is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
75.50%
5Y equity/share CAGR at 75-90% of TRAW's 100.31%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
-75.29%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Negative asset growth while TRAW invests at 250.59%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-36.19%
We have a declining book value while TRAW shows 157.40%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-16.18%
We cut SG&A while TRAW invests at 8.73%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.